Research programme: phosphotransferase inhibitors - Ignyta

Drug Profile

Research programme: phosphotransferase inhibitors - Ignyta

Alternative Names: RXDX-102; RXDX-103; RXDX-104

Latest Information Update: 29 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nerviano Medical Sciences
  • Developer Ignyta
  • Class
  • Mechanism of Action CDC7 protein kinase inhibitors; Proto oncogene protein c ret inhibitors; TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 14 Mar 2016 Ignyta has patent protection for RXDX 103 in USA (Ignyta 10-K, March 2016)
  • 26 Feb 2016 Ignyta discontinues development RXDX 103 in USA for Cancer (Ignyta 10-K, March 2016)
  • 15 Dec 2014 Nerviano and Ignyta amend licensing agreement
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top